Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
5
6
2020
medline:
3
3
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Programmed death ligand (PD-L1)-based immune checkpoint blockade therapy for metastatic renal cell carcinoma (RCC) achieves significant response rates in a subgroup of patients. The relevance of PD-L1 gene regulation for disease outcome is not clear. To evaluate PD-L1 expression and its dependence on interferon-γ (IFN-γ) in RCC cell lines and tissues in relation to disease outcome. Regulation of PD-L1-mRNA and PD-L1 protein was studied in cell lines from clear cell RCC (ccRCC) and papillary RCC (pRCC) by quantitative RT-PCR and Western-blot analysis. PD-L1-mRNA correlation and gene-set enrichment analysis (GSEA) of the IFN-γ pathway were conducted with RNA-Seq from ccRCC, pRCC, and skin cutaneous melanoma (SKCM) tissue. In addition, patient overall survival (OS) and disease-free survival (DFS) (cBioPortal for Cancer Genomics) were considered. In ccRCC-like cell lines, PD-L1 was induced by canonical IFN-γ signaling, whereas in a pRCC-like cell line, PD-L1 was refractory towards IFN-γ signaling. In ccRCC and SKCM tissues, GSEA revealed significant IFN-γ pathway activation in tissue samples with high PD-L1-mRNA levels. This was not observed in pRCC tissue. ccRCC and SKMC patients with low PD-L1-mRNA levels had significantly shorter OS and DFS than those with high PD-L1-mRNA levels. In pRCC patients, no significant difference in OS and DFS with regard to PD-L1-mRNA tissue levels was obvious. The findings suggest that ccRCC and pRCC differ with respect to PD-L1 regulation by IFN-γ-signaling. High PD-L1-mRNA levels in tumor tissues with a positive IFN-γ signature favorably affect OS and DFS.
Sections du résumé
BACKGROUND
Programmed death ligand (PD-L1)-based immune checkpoint blockade therapy for metastatic renal cell carcinoma (RCC) achieves significant response rates in a subgroup of patients. The relevance of PD-L1 gene regulation for disease outcome is not clear.
OBJECTIVE
To evaluate PD-L1 expression and its dependence on interferon-γ (IFN-γ) in RCC cell lines and tissues in relation to disease outcome.
METHODS AND PATIENTS
Regulation of PD-L1-mRNA and PD-L1 protein was studied in cell lines from clear cell RCC (ccRCC) and papillary RCC (pRCC) by quantitative RT-PCR and Western-blot analysis. PD-L1-mRNA correlation and gene-set enrichment analysis (GSEA) of the IFN-γ pathway were conducted with RNA-Seq from ccRCC, pRCC, and skin cutaneous melanoma (SKCM) tissue. In addition, patient overall survival (OS) and disease-free survival (DFS) (cBioPortal for Cancer Genomics) were considered.
RESULTS
In ccRCC-like cell lines, PD-L1 was induced by canonical IFN-γ signaling, whereas in a pRCC-like cell line, PD-L1 was refractory towards IFN-γ signaling. In ccRCC and SKCM tissues, GSEA revealed significant IFN-γ pathway activation in tissue samples with high PD-L1-mRNA levels. This was not observed in pRCC tissue. ccRCC and SKMC patients with low PD-L1-mRNA levels had significantly shorter OS and DFS than those with high PD-L1-mRNA levels. In pRCC patients, no significant difference in OS and DFS with regard to PD-L1-mRNA tissue levels was obvious.
CONCLUSIONS
The findings suggest that ccRCC and pRCC differ with respect to PD-L1 regulation by IFN-γ-signaling. High PD-L1-mRNA levels in tumor tissues with a positive IFN-γ signature favorably affect OS and DFS.
Identifiants
pubmed: 32495158
doi: 10.1007/s11523-020-00728-8
pii: 10.1007/s11523-020-00728-8
pmc: PMC7283197
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-390Références
Cancer Immunol Immunother. 2018 Mar;67(3):403-412
pubmed: 29150702
In Vivo. 2000 May-Jun;14(3):393-400
pubmed: 10904872
Int J Mol Sci. 2017 Jun 21;18(6):
pubmed: 28635644
Signal Transduct Target Ther. 2018 Sep 28;3:26
pubmed: 30275987
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1439-44
pubmed: 21220347
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Nature. 1985 Jun 20-26;315(6021):672-6
pubmed: 3925348
Oncotarget. 2015 May 30;6(15):13506-19
pubmed: 25940795
Cancer Res. 2007 Apr 1;67(7):3171-6
pubmed: 17409424
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
J Exp Med. 1998 Mar 16;187(6):875-83
pubmed: 9500790
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Clin Cancer Res. 2015 Mar 1;21(5):1071-7
pubmed: 25538263
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Immunity. 2017 Dec 19;47(6):1007-1009
pubmed: 29262340
Onco Targets Ther. 2018 Oct 04;11:6505-6524
pubmed: 30323625
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
Br J Cancer. 2015 Apr 28;112(9):1421-7
pubmed: 25856776
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Pathol Oncol Res. 2020 Apr;26(2):651-663
pubmed: 31748880
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
J Immunol. 2009 Feb 1;182(3):1325-33
pubmed: 19155478
Nature. 2017 Sep 7;549(7670):101-105
pubmed: 28813417
Nat Commun. 2017 May 10;8:15165
pubmed: 28489074
J Biol Chem. 2017 Dec 15;292(50):20683-20693
pubmed: 29066622
Cancer Gene Ther. 2001 Jul;8(7):529-36
pubmed: 11498775
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Eur Urol. 2019 Aug;76(2):151-156
pubmed: 31151678